GLUT1 targeting trial for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study looks at stored blood samples from adults with type 1 diabetes to understand how a protein called GLUT1 affects the immune system. The goal is to find new ways to control autoimmunity, which could lead to better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older at the time your blood sample was taken.
- You must have a confirmed diagnosis of type 1 diabetes.
- Your blood sample must already be stored in the San Raffaele Hospital biobank and you must have previously agreed to let it be used for research.
- You cannot have other major health problems that could affect the study results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at children who have just started insulin for new-onset type 1 diabetes. It aims to test an intervention early in the course of the disease, which may help change how the immune system and diabetes progress.
This study looks at immune (defense system) and blood-sugar changes in people with type 1 diabetes, and in some other diabetes or autoimmune hormone conditions. It includes people who will have a specific abdominal surgery so doctors can safely study lymph node tissue.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This study looks at immune cells in children who were recently diagnosed with type 1 diabetes. It involves one extra blood draw to better understand how the immune system attacks the pancreas. If you join, no new treatments are given—just observation and analysis of your child's immune cells.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This study follows people who have islet autoantibodies (markers in the blood that can increase the risk of type 1 diabetes) but do not have diabetes yet. The goal is to better understand how these antibodies affect health over time.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.